Published in Ann Rheum Dis on January 07, 2005
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A (2006) 3.11
EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis (2009) 2.20
B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther (2006) 1.72
Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther (2009) 1.61
Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis (2006) 1.45
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis (2006) 1.38
The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys (2008) 1.23
NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med (2013) 1.12
Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis (2006) 1.12
Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes. Arthritis Res Ther (2011) 1.08
Cytokines in Sjögren's syndrome. Oral Dis (2009) 0.98
Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjögren's syndrome. Oral Dis (2011) 0.92
Immunopathologic differences of Sjögren's syndrome versus sicca syndrome in HCV and HIV infection. Arthritis Res Ther (2011) 0.90
Active immunological profile is associated with systemic Sjögren's syndrome. J Clin Immunol (2011) 0.88
No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren's syndrome. Arthritis Res Ther (2006) 0.84
Biologic treatments for systemic rheumatic diseases. Oral Dis (2008) 0.79
Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome. Arthritis Res Ther (2007) 0.78
Distribution of Peripheral Lymphocyte Populations in Primary Sjögren's Syndrome Patients. J Immunol Res (2015) 0.77
Treating Sjögren's Syndrome: Insights for the Clinician. Ther Adv Musculoskelet Dis (2010) 0.77
Could the complement component C4 or its fragment C4d be a marker of the more severe conditions in patients with primary Sjögren's syndrome? Rheumatol Int (2013) 0.77
Serum 25-Hydroxyvitamin D3 and BAFF Levels Are Associated with Disease Activity in Primary Sjogren's Syndrome. J Immunol Res (2016) 0.75
Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Front Med (Lausanne) (2017) 0.75
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med (1999) 7.41
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med (1999) 6.27
BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science (1999) 5.99
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem (1990) 4.02
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum (2001) 3.72
BAFF: a fundamental survival factor for B cells. Nat Rev Immunol (2002) 2.94
Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection. Lancet (1992) 2.79
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum (2003) 2.47
Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren's syndrome. Arthritis Rheum (1986) 2.39
The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis (2003) 2.34
Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med (1983) 1.68
Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum (2002) 1.59
Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. J Pathol (2004) 1.46
In primary Sjögren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum (2003) 1.36
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients. Blood (1984) 1.26
A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis (2001) 1.22
Beta2 microglobulin and lymphocytic infiltration in Sjögren's syndrome. N Engl J Med (1975) 1.19
Reappraisal of serum beta2-microglobulin as marker of GFR. Ren Fail (2001) 1.18
Elevated salivary and synovial fluid beta2-microglobulin in Sjogren's syndrome and rheumatoid arthritis. Science (1975) 1.13
Primary Sjögren's syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) (1999) 1.08
Beta 2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells. Blood (2003) 1.02
Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med (1988) 1.01
The diagnosis value of beta 2-microglobulin and immunoglobulins in primary Sjögren's syndrome. Clin Rheumatol (1995) 1.01
Salivary gland lymphomas in patients with Sjögren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum (2000) 0.99
Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus (1996) 0.98
Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjögren's syndrome. Curr Rheumatol Rep (2003) 0.96
Subclinical lung inflammation in primary Sjögren's syndrome. Relationship between bronchoalveolar lavage cellular analysis findings and characteristics of the disease. Arthritis Rheum (1987) 0.94
Ro/SS-A and La/SS-B antibody level variation in patients with Sjögren's syndrome and systemic lupus erythematosus. J Autoimmun (1998) 0.93
Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 0.93
An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer (2002) 0.92
Outcome measures in Sjögren's syndrome. Rheumatology (Oxford) (2001) 0.91
Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis (1999) 0.90
Salivary and serum beta2-microglobulin and gamma-glutamyl-transferase in patients with primary Sjögren syndrome and Sjögren syndrome secondary to systemic lupus erythematosus. Clin Chim Acta (2003) 0.90
Beta2-microglobulin as a potential initiator of inflammatory responses. Trends Immunol (2003) 0.85
Antitumor effect of beta2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-kappaB. Cancer Res (2001) 0.85
Primary Sjögren's syndrome--clinical and laboratory markers of disease activity. Semin Arthritis Rheum (1992) 0.85
Pulmonary findings in patients with primary Sjögren's syndrome. Chest (1995) 0.84
Elevated serum beta-2-microglobulin--a prognostic marker for development of AIDS among patients with persistent generalized lymphadenopathy. Infection (1988) 0.80
The effect of human beta2-microglobulin on major histocompatibility complex I peptide loading and the engineering of a high affinity variant. Implications for peptide-based vaccines. J Biol Chem (1998) 0.79
Processing of exogenous hepatitis B surface antigen particles for Ld-restricted epitope presentation depends on exogenous beta2-microglobulin. Eur J Immunol (1997) 0.78
Factors predictive of renal involvement in patients with primary Sjögren's syndrome. Clin Nephrol (2001) 0.77
Increased risk of lymphoma in sicca syndrome. Ann Intern Med (1978) 4.63
Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med (1979) 4.52
Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol (2001) 3.87
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum (2009) 2.92
Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood (1991) 2.92
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med (2001) 2.87
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis (2007) 2.75
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest (1997) 2.48
Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest (1996) 2.39
The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis (2003) 2.34
Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med (Berl) (2005) 2.29
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus (2002) 2.03
Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med (1986) 2.01
Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum (2001) 2.00
Management of nontuberculous infectious discitis. treatments used in 110 patients admitted to 12 teaching hospitals in France. Joint Bone Spine (2001) 1.98
Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med (1978) 1.96
Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum (2009) 1.88
Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol (2001) 1.84
Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol (1999) 1.80
Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol (1994) 1.76
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody. J Exp Med (1986) 1.75
Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun (2011) 1.70
Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function. J Clin Invest (1992) 1.69
A systematic study of HLA class II-beta DNA restriction fragments in insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A (1985) 1.69
Detection of Borrelia burgdorferi DNA in muscle of patients with chronic myalgia related to Lyme disease. Am J Med (1998) 1.66
Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis (2010) 1.59
Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun (2008) 1.53
Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities. J Clin Invest (1990) 1.51
The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Français d'Etude Génétique des Spondylarthropathies. Arthritis Rheum (2000) 1.51
Regulation of phagocytosis and [Ca2+]i flux by distinct regions of an Fc receptor. Science (1991) 1.48
Genome scan of human systemic lupus erythematosus by regression modeling: evidence of linkage and epistasis at 4p16-15.2. Am J Hum Genet (2000) 1.47
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum (2010) 1.47
Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis (2006) 1.45
STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum (2009) 1.43
Prevalence of hepatitis G virus RNA in French blood donors and recipients. Transfusion (1997) 1.42
Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant (2006) 1.42
C-reactive protein binding to FcgammaRIIa on human monocytes and neutrophils is allele-specific. J Clin Invest (2000) 1.42
[Sjögren's syndrome. Relation to viral infections]. Presse Med (1993) 1.41
Granulocytic sarcoma (chloroma): imaging findings in adults and children. AJR Am J Roentgenol (2002) 1.41
Low-grade MALT lymphoma mimicking Waldenström's macroglobulinemia. Leukemia (1999) 1.38
Fc gamma receptor III induces actin polymerization in human neutrophils and primes phagocytosis mediated by Fc gamma receptor II. J Immunol (1991) 1.38
Autoimmune and inflammatory disorders and risk of malignant lymphomas--an update. J Intern Med (2008) 1.38
Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun (2002) 1.37
Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol (1984) 1.36
Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy (2013) 1.35
Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Ann Rheum Dis (2004) 1.35
HLA genotype studies in juvenile insulin-dependent diabetes. Diabetologia (1980) 1.34
Treatment of lupus with corticosteroids. Lupus (2001) 1.34
Aspirin-induced depression of renal function. N Engl J Med (1977) 1.33
Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med (1978) 1.33
Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood (1983) 1.32
Defective Fc receptor-mediated function of the mononuclear phagocyte system in lupus nephritis. Ann Intern Med (1982) 1.31
A serial study of splenic reticuloendothelial system Fc receptor functional activity in systemic lupus erythematosus. Arthritis Rheum (1982) 1.31
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis (2004) 1.29
A single amino acid distinguishes the high-responder from the low-responder form of Fc receptor II on human monocytes. Eur J Immunol (1991) 1.26
Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation (2001) 1.25
Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken) (2010) 1.25
Opsonin-independent ligation of Fc gamma receptors. The 3G8-bearing receptors on neutrophils mediate the phagocytosis of concanavalin A-treated erythrocytes and nonopsonized Escherichia coli. J Exp Med (1987) 1.21
Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis (2007) 1.21
NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis. Ann Rheum Dis (2010) 1.19
HLA haplotype study of 53 juvenile insulin-dependent diabetic (I.D.D.) families. Tissue Antigens (1982) 1.19
Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis (2004) 1.19
HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol (2000) 1.18
Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis (2004) 1.18
Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. J Immunol (1997) 1.17
High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med (1981) 1.17
Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis (2012) 1.16
Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens (2001) 1.15
Genetic associations of LYN with systemic lupus erythematosus. Genes Immun (2009) 1.15
Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis (2011) 1.15
Opposing functions of ATF2 and Fos-like transcription factors in c-Jun-mediated myogenin expression and terminal differentiation of avian myoblasts. Oncogene (2001) 1.14
Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum (2006) 1.14
Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) (2002) 1.12
The PTPN22 620W allele confers susceptibility to systemic sclerosis: findings of a large case-control study of European Caucasians and a meta-analysis. Arthritis Rheum (2008) 1.11
Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis (2006) 1.11
B-cell activating factor of the tumour necrosis factor family expression in blood monocytes and T cells from patients with primary Sjögren's syndrome. Scand J Immunol (2008) 1.11
Defective mononuclear phagocyte function in systemic lupus erythematosus: dissociation of Fc receptor-ligand binding and internalization. J Immunol (1984) 1.10
Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis (2012) 1.09
Impaired fc-mediated mononuclear phagocyte system clearance in HLA-DR2 and MT1-positive healthy young adults. J Exp Med (1983) 1.09
Analysis of HLA class I genes with restriction endonuclease fragments: implications for polymorphism of the human major histocompatibility complex. Proc Natl Acad Sci U S A (1983) 1.09
A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun (2012) 1.08
Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun (2011) 1.07
Direct molecular typing of Borrelia burgdorferi sensu lato species in synovial samples from patients with lyme arthritis. J Clin Microbiol (2000) 1.07
Rheumatic disorders developed after hepatitis B vaccination. Rheumatology (Oxford) (1999) 1.07